Overview

Safety and Biomarker Study of EPI-589 in Parkinson's Disease

Status:
Completed
Trial end date:
2019-04-16
Target enrollment:
Participant gender:
Summary
Open-label study with 30-day run-in phase and adaptive design component to include more subjects if deemed appropriate by investigators.
Phase:
Phase 2
Details
Lead Sponsor:
Edison Pharmaceuticals Inc
PTC Therapeutics